BioScrip Reports Third Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/4/2026
- S&P 500, Dow hit record highs on strong AI-linked earnings, Mideast deal hopes
- Caterpillar stock jumps on strong earnings and revenue beat
- Optical component stocks rally on proposed U.S. ban on Chinese tech
- BofA says this memory stock could double. Here are 5 reasons why
- Merck shares rise on big Q2 earnings beat, adjusted FY outlook
- Palantir posts 93% revenue growth in Q2 2026, raises full-year outlook
- Nutanix to cut 5% of workforce, expects up to $43M in charges
- Grainger CFO resigns, interim replacement named
- Microsoft joins, Broadcom exits Goldman's top-stocks list
- Walmart dips after Oppenheimer downgrades shares on difficult short-term setup
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
Jefferies Resumes BioScrip (BIOS) at Buy
November 8, 2016 7:22 AM ESTJefferies resumes coverage on BioScrip (NASDAQ: BIOS) with a Buy rating and a price target of $2.50.
Analyst Brian Tanquilut commented, "We were surprised by BIOS's disappointing Q3 and the resulting guidance cut, and recognize that it further dents the company's already-weak credibility... More
BioScrip (BIOS) Misses Q3 EPS by 7c
November 7, 2016 5:19 PM ESTBioScrip (NASDAQ: BIOS) reported Q3 EPS of ($0.12), $0.07 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $224.5 million versus the consensus estimate of $223.26 million.
The Company reconfirms its plan to achieve between $14 million to $17 million in Home Solutions cost synergies... More
